CAPR stock news · Capricor Therapeutics
Get alerts for CAPR
Follow Capricor Therapeutics (CAPR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CAPROn Friday evening, 12 health care stocks changed a lot in price, with Inovio up 292.6% and Precigen down 26.5%.
NeutralCapricor shares rose 12% in Friday's after-hours session. The article gives no company update that changes its business outlook.
Why is Capricor Therapeutics' stock moving today?
Bad for CAPRCapricor reported better arm-function results in its extension study, but FDA staff said the combined trial evidence does not establish effectiveness. That weakens the drug’s approval case.
Capricor Therapeutics shares rise on Monday following FDA's extension of deramiocel's PDUFA action date.
NeutralCapricor Therapeutics Inc's stock is trading higher following the FDA's decision to extend the PDUFA target action date for its drug deramiocel, indicating continued regulatory review without a request for additional data.
Kaos Capital raises concerns regarding Capricor's rapid cash depletion.
Bad for CAPRCapricor Therapeutics is facing increased scrutiny from activist investor Kaos Capital, which is pushing for immediate governance changes and a cash preservation strategy due to significant cash burn. This situation raises concerns about the company's financial health and strategic direction, potentially impacting investor sentiment and stock performance.
Capricor Therapeutics expresses confidence in the FDA's forthcoming decision on Deramiocel.
NeutralCapricor Therapeutics' stock is trading higher following the release of its second-quarter earnings and ongoing discussions with the FDA regarding the approval of Deramiocel. The company has addressed regulatory concerns and is preparing for a potential commercial launch, which could enhance investor confidence and drive stock performance.
After-hours trading sees Capricor Therapeutics (CAPR) stock jump more than 67% following earnings report details.
NeutralCapricor Therapeutics' shares soared over 67% after hours following the release of its second-quarter earnings report, which included a significant loss but highlighted an ongoing FDA review of its Biologics License Application. The market reacted positively to the potential for future approval and the company's assurance of sufficient cash to fund operations for the next year.
Transcript of Capricor Therapeutics' Q2 2026 earnings call released.
NeutralCapricor Therapeutics' Q2 2026 earnings call revealed a significant net loss and ongoing regulatory challenges with their lead product, deramcicel, which could lead to negative market reactions as investors assess the implications for the company's future.